A Study to Evaluate the Pandemic Response Optimizing Technology and Ethics for Coronavirus Teams Implementing Novel Genetics

Overview

About this study

The purpose of this study is to explore lay understandings toward participating in and perceptions of consent to biospecimen research and valuation of genetics in SARS-COV-2 infection, testing, immunity, and vaccine development, to explore professional attitudes toward and perception of barriers and facilitators for implementating genetic technology to facilitate understanding of SARS-COV-2 infection and immunity, improvement and scale-up of testing, and vaccine development, and to identify ethical, social, and inter-professional aspects of microbial genetic technology implementation in population health surveillance, clinical test development, and vaccine research.We hypothesize that engagement with individuals whom directly experience and/or are impacted by the increasing use of SARS-Cov-2 genetic technology, including COVID-19 Pandemic Response Biobank contributors and interdisciplinary expert teams will help identify ethical and social issues in adopting and implementing emerging technology.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Ability to converse in English.
Legal adult 18 years of age or older who have the capacity to consent to participating in this study.
To meet Aims 1 and 2 and to ensure balanced stakeholder perspectives are gathered, eligible participants will be screened to identify employees of Mayo Clinic (currently employed by Mayo Clinic or employed by Mayo Clinic within the last five years) and non-employee (currently not employed by Mayo Clinic or employed by Mayo Clinic in the last five years).
To meet the aims of this study, equilibrium of the number of eligible participants in the groups of the subject populations identified is desirable thus selective sampling of the groups will be implemented during recruitment

Exclusion Criteria:

Unable to converse in English.
Individuals less than 18 years of age or who do not have the capacity to consent to participating in this study.
Legally authorized representatives of contributors to the biobank
To meet Aims 1 and 2, eligible participants in subject population group 1 will be screened to identify current participation in the Mayo Clinic Center for Individualized Medicine Biobank.
Individuals who have donated to the Mayo Clinic.
Biobank will be excluded from this study to safeguard an unbiased data collection on biospecimen research and perceptions of consent and voluntariness during a pandemic.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Karen Meagher, Ph.D.	Closed-enrolling by invitation What is this? (?) "Close" Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.	Contact information: Sara Watson M.A. (507) 538-3543 Watson.Sara1@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Karen Meagher, Ph.D.

Closed-enrolling by invitation

Contact information:

Sara Watson M.A.

(507) 538-3543

Watson.Sara1@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials